Our Insights Oncology Anthony Iannacci 8/18/26 Oncology Anthony Iannacci 8/18/26 Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved Read More Oncology Anthony Iannacci 7/12/22 Oncology Anthony Iannacci 7/12/22 Enhertu shows high clinical innovation in second-line metastatic breast cancer Read More Want to get in touch? Click here
Oncology Anthony Iannacci 8/18/26 Oncology Anthony Iannacci 8/18/26 Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved Read More
Oncology Anthony Iannacci 7/12/22 Oncology Anthony Iannacci 7/12/22 Enhertu shows high clinical innovation in second-line metastatic breast cancer Read More
